Total Payments
$14,213
2024 Payments
$936.22
Companies
37
Transactions
265
Medicare Patients
15,093
Medicare Billing
$718,764
Payment Breakdown by Category
Consulting$7,056 (49.6%)
Food & Beverage$5,004 (35.2%)
Travel$2,153 (15.2%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $7,056 | 2 | 49.6% |
| Food and Beverage | $5,004 | 256 | 35.2% |
| Travel and Lodging | $2,153 | 7 | 15.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Abbott Laboratories | $7,248 | 5 | $0 (2023) |
| Medtronic Vascular, Inc. | $2,741 | 19 | $0 (2018) |
| Novartis Pharmaceuticals Corporation | $794.74 | 52 | $0 (2024) |
| Boston Scientific Corporation | $407.08 | 11 | $0 (2024) |
| PFIZER INC. | $383.35 | 26 | $0 (2024) |
| Merck Sharp & Dohme LLC | $325.33 | 21 | $0 (2024) |
| Amgen Inc. | $303.34 | 20 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $240.66 | 16 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $237.70 | 17 | $0 (2024) |
| CVRx, Inc. | $206.44 | 7 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $936.22 | 53 | Novartis Pharmaceuticals Corporation ($193.23) |
| 2023 | $1,332 | 59 | Novartis Pharmaceuticals Corporation ($226.08) |
| 2022 | $566.37 | 38 | Merck Sharp & Dohme LLC ($133.17) |
| 2021 | $408.82 | 25 | Novartis Pharmaceuticals Corporation ($124.06) |
| 2020 | $85.23 | 6 | PFIZER INC. ($42.71) |
| 2019 | $3,922 | 29 | Abbott Laboratories ($3,542) |
| 2018 | $3,838 | 13 | Abbott Laboratories ($3,681) |
| 2017 | $3,125 | 42 | Medtronic Vascular, Inc. ($2,729) |
All Payment Transactions
265 individual payment records from CMS Open Payments — Page 1 of 11
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $15.50 | General |
| Category: Cardiology | ||||||
| 12/03/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $15.50 | General |
| Category: Cardiovascular | ||||||
| 12/02/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug), ENTRESTO | Food and Beverage | In-kind items and services | $15.78 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/14/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $16.88 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/13/2024 | Azurity Pharmaceuticals, Inc. | EDARBI (Drug) | Food and Beverage | In-kind items and services | $15.00 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/08/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $3.01 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/28/2024 | Cleerly, Inc. | Cleerly Ischemia (Device), Cleerly Labs | Food and Beverage | In-kind items and services | $14.79 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/21/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug), ENTRESTO | Food and Beverage | In-kind items and services | $17.88 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/15/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $13.75 | General |
| Category: Cardiovascular | ||||||
| 10/07/2024 | PFIZER INC. | ELIQUIS (Drug) | Food and Beverage | In-kind items and services | $17.24 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 09/27/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $16.42 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 09/23/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $18.84 | General |
| Category: Obesity | ||||||
| 09/17/2024 | Philips North America LLC | (CK4) MCOT (Device) | Food and Beverage | Cash or cash equivalent | $24.03 | General |
| Category: Medical Device | ||||||
| 08/29/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $17.89 | General |
| Category: Cardiology | ||||||
| 08/22/2024 | Azurity Pharmaceuticals, Inc. | EDARBI (Drug) | Food and Beverage | In-kind items and services | $14.64 | General |
| Category: CARDIOVASCULAR | ||||||
| 08/19/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $15.78 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 08/13/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $15.99 | General |
| Category: CARDIOVASCULAR | ||||||
| 08/05/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug), ENTRESTO | Food and Beverage | In-kind items and services | $16.12 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 07/18/2024 | Azurity Pharmaceuticals, Inc. | EDARBI (Drug) | Food and Beverage | In-kind items and services | $15.79 | General |
| Category: CARDIOVASCULAR | ||||||
| 07/01/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $20.88 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 06/24/2024 | PFIZER INC. | ELIQUIS (Drug) | Food and Beverage | In-kind items and services | $16.60 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 06/20/2024 | Boston Scientific Corporation | WATCHMAN FLX (Device) | Food and Beverage | In-kind items and services | $29.97 | General |
| Category: WATCHMAN FLX_IC | ||||||
| 06/10/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $18.59 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 06/10/2024 | Alnylam Pharmaceuticals Inc. | ONPATTRO (Drug) | Food and Beverage | In-kind items and services | $15.73 | General |
| Category: Genetic Disease | ||||||
| 06/06/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $15.95 | General |
| Category: CARDIOVASCULAR | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 17 | 4,124 | 6,834 | $1.6M | $195,756 |
| 2022 | 19 | 3,656 | 5,760 | $1.2M | $163,410 |
| 2021 | 23 | 3,816 | 6,467 | $961,111 | $174,186 |
| 2020 | 26 | 3,497 | 6,451 | $674,436 | $185,412 |
Total Patients
15,093
Total Services
25,512
Medicare Billing
$718,764
Procedure Codes
93
All Medicare Procedures & Services
93 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 207 | 383 | $322,041 | $40,676 | 12.6% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 159 | 393 | $359,533 | $40,331 | 11.2% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2023 | 2,555 | 3,519 | $142,559 | $23,842 | 16.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 136 | 197 | $117,384 | $14,432 | 12.3% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 86 | 96 | $120,171 | $14,298 | 11.9% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 87 | 185 | $89,617 | $12,473 | 13.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 64 | 70 | $81,990 | $10,243 | 12.5% |
| 93294 | Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | Office | 2023 | 138 | 414 | $79,426 | $9,624 | 12.1% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 253 | 584 | $58,960 | $7,096 | 12.0% |
| 93296 | Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | Office | 2023 | 168 | 380 | $60,380 | $7,055 | 11.7% |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and tec | Office | 2023 | 24 | 143 | $38,610 | $4,978 | 12.9% |
| 93298 | Evaluation of cardiac rhythm monitor system, remote up to 30 days | Office | 2023 | 26 | 179 | $29,781 | $3,714 | 12.5% |
| 93295 | Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | Office | 2023 | 39 | 106 | $24,810 | $2,879 | 11.6% |
| 93288 | Evaluation of single, dual, multiple lead or leadless pacemaker system | Office | 2023 | 28 | 31 | $11,928 | $1,473 | 12.3% |
| 93016 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | Facility | 2023 | 55 | 55 | $7,394 | $949.52 | 12.8% |
| 93289 | Evaluation of single, dual, or multiple lead implantable defibrillator system | Office | 2023 | 12 | 12 | $5,928 | $651.74 | 11.0% |
| 93018 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | Facility | 2023 | 55 | 55 | $4,891 | $625.56 | 12.8% |
| 93016 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | Office | 2023 | 16 | 16 | $2,168 | $237.38 | 10.9% |
| 93018 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | Office | 2023 | 16 | 16 | $1,436 | $177.26 | 12.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 181 | 272 | $229,398 | $29,500 | 12.9% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 135 | 246 | $164,397 | $21,609 | 13.1% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 126 | 333 | $150,316 | $20,170 | 13.4% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2022 | 2,097 | 2,845 | $99,575 | $19,225 | 19.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 147 | 208 | $124,697 | $14,987 | 12.0% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 84 | 89 | $111,695 | $14,828 | 13.3% |
About Dr. Nicholas Tullo, MD
Dr. Nicholas Tullo, MD is a Cardiovascular Disease healthcare provider based in West Orange, New Jersey. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/19/2005. The National Provider Identifier (NPI) number assigned to this provider is 1982603239.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Nicholas Tullo, MD has received a total of $14,213 in payments from pharmaceutical and medical device companies, with $936.22 received in 2024. These payments were reported across 265 transactions from 37 companies. The most common payment nature is "Consulting Fee" ($7,056).
As a Medicare-enrolled provider, Tullo has provided services to 15,093 Medicare beneficiaries, totaling 25,512 services with total Medicare billing of $718,764. Data is available for 4 years (2020–2023), covering 93 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Other Specialties Clinical Cardiac Electrophysiology
- Location West Orange, NJ
- Active Since 07/19/2005
- Last Updated 02/16/2010
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1982603239
Products in Payments
- Ensite Cardiac Mapping System (Device) $3,681
- ViewMate Intracardiac Echo (Device) $3,528
- Micra (Device) $1,201
- ENTRESTO (Drug) $578.62
- ELIQUIS (Drug) $506.19
- VERQUVO (Drug) $325.33
- Repatha (Biological) $240.35
- LEQVIO (Drug) $216.12
- Barostim Neo System (Device) $206.44
- MULTAQ (Drug) $127.01
- LifeVest (Device) $125.97
- PRALUENT (Drug) $113.65
- XARELTO (Drug) $109.55
- Hillrom - Cardiac Ambulatory Monitor (Device) $104.85
- WATCHMAN FLX (Device) $102.31
- WATCHMAN (Device) $94.25
- Edarbi (Drug) $92.02
- Resolute (Device) $74.31
- SYNERGY ABLATION SYSTEM (Device) $67.16
- Corlanor (Drug) $62.99
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in West Orange
Marc Roelke, M.d, M.D
Cardiovascular Disease — Payments: $273,645
Cardiovascular Disease $273,645
Fadi Chaaban, M.d, M.D
Cardiovascular Disease — Payments: $209,860
Cardiovascular Disease $209,860
Sabino Torre, M.d, M.D
Cardiovascular Disease — Payments: $115,814
Cardiovascular Disease $115,814
Abbas Shehadeh, Md, MD
Cardiovascular Disease — Payments: $65,125
Cardiovascular Disease $65,125
Constantinos Costeas, M.d, M.D
Cardiovascular Disease — Payments: $18,617
Cardiovascular Disease $18,617
Gary Berman, Md, MD
Cardiovascular Disease — Payments: $16,628
Cardiovascular Disease $16,628